Low-Dose CBD Enhanced Opioid Pain Relief Without Adding Side Effects
In a double-blind RCT, 50 mg CBD enhanced the acute pain-relieving effects of hydromorphone without increasing adverse effects, while 200 mg CBD increased both pain relief and bad effects.
Quick Facts
What This Study Found
When combined with hydromorphone (which alone did not reliably produce analgesia), CBD increased analgesic effects for some acute pain measures but not chronic pain models. At 50 mg, CBD enhanced analgesia without additional adverse effects. At 200 mg, there were concurrent increases in self-reported "bad effects." CBD also mitigated the psychomotor impairment caused by hydromorphone alone.
Key Numbers
31 participants. 5 drug conditions. Hydromorphone 4mg + CBD 0, 50, 100, or 200mg. 50mg CBD enhanced acute analgesia without bad effects. 200mg CBD increased both analgesia and bad effects. CBD mitigated hydromorphone-induced psychomotor impairment.
How They Did This
Within-subjects, double-blind, double-dummy, randomized human laboratory trial with 31 healthy participants. Five conditions: placebo+placebo, hydromorphone+placebo, hydromorphone+50mg CBD, hydromorphone+100mg CBD, hydromorphone+200mg CBD. Quantitative sensory testing, subjective drug effects, and psychomotor assessments at multiple time points.
Why This Research Matters
If low-dose CBD can enhance opioid analgesia, patients might need lower opioid doses, reducing addiction risk. The finding that CBD also reduced opioid-related psychomotor impairment adds a potential safety benefit.
The Bigger Picture
The opioid crisis has created urgent demand for opioid-sparing strategies. Low-dose CBD enhancing opioid analgesia while reducing psychomotor impairment is a promising combination that warrants larger clinical trials.
What This Study Doesn't Tell Us
Small sample (n=31) of healthy volunteers, not chronic pain patients. Laboratory pain models may not reflect clinical pain. Single-dose design. Effects of repeated dosing are unknown.
Questions This Raises
- ?Would these results translate to chronic pain patients?
- ?What is the optimal CBD dose for opioid-sparing effects?
- ?Would this approach work with other opioids?
Trust & Context
- Key Stat:
- 50 mg CBD enhanced opioid analgesia without adding side effects
- Evidence Grade:
- Strong: randomized, double-blind, placebo-controlled, within-subjects design with multiple dose levels, though small sample of healthy volunteers
- Study Age:
- Published in 2025
- Original Title:
- A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model.
- Published In:
- Pain, 166(9), e175-e184 (2025)
- Authors:
- Bergeria, Cecilia L(7), Mun, Chung Jung(7), Speed, Traci J(2), Huhn, Andrew S, Wolinsky, David, Vandrey, Ryan, Campbell, Claudia M, Dunn, Kelly E
- Database ID:
- RTHC-06051
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Can CBD replace opioids for pain?
This study did not test CBD alone for pain. It found that adding low-dose CBD (50 mg) to a sub-therapeutic opioid dose enhanced pain relief for acute pain without additional side effects. This suggests CBD may allow lower opioid doses rather than replacing them entirely.
Why did higher CBD doses cause problems?
At 200 mg, CBD increased both pain relief and self-reported "bad effects." The 50 mg dose appeared to hit a sweet spot of enhanced analgesia without adverse effects, suggesting that more CBD is not necessarily better.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06051APA
Bergeria, Cecilia L; Mun, Chung Jung; Speed, Traci J; Huhn, Andrew S; Wolinsky, David; Vandrey, Ryan; Campbell, Claudia M; Dunn, Kelly E. (2025). A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model.. Pain, 166(9), e175-e184. https://doi.org/10.1097/j.pain.0000000000003561
MLA
Bergeria, Cecilia L, et al. "A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model.." Pain, 2025. https://doi.org/10.1097/j.pain.0000000000003561
RethinkTHC
RethinkTHC Research Database. "A within-subject, double-blind, placebo-controlled randomize..." RTHC-06051. Retrieved from https://rethinkthc.com/research/bergeria-2025-a-withinsubject-doubleblind-placebocontrolled
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.